• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Articles published by Vera Therapeutics

    Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock
    From Vera Therapeutics
    Via GlobeNewswire
    Tickers VERA
    Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock
    From Vera Therapeutics
    Via GlobeNewswire
    Tickers VERA
    Vera Therapeutics Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN in a Late-Breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024
    From Vera Therapeutics
    Via GlobeNewswire
    Tickers VERA
    Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Vera Therapeutics
    Via GlobeNewswire
    Tickers VERA
    Vera Therapeutics Announces Late-Breaking Oral Presentation of ORIGIN Phase 2b Long-term Results at the American Society of Nephrology Kidney Week 2024
    From Vera Therapeutics
    Via GlobeNewswire
    Tickers VERA
    Vera Therapeutics Announces Expanded Atacicept Development Program In Multiple Autoimmune Kidney Diseases
    From Vera Therapeutics
    Via GlobeNewswire
    Tickers VERA
    Vera Therapeutics to Host In-Person R&D Day in New York to Discuss Potential Indication Expansion for Atacicept on October 2, 2024
    From Vera Therapeutics
    Via GlobeNewswire
    Tickers VERA
    Vera Therapeutics Completes Enrollment for Primary Endpoint in Pivotal Phase 3 ORIGIN 3 Trial of Atacicept in IgAN
    From Vera Therapeutics
    Via GlobeNewswire
    Tickers VERA
    Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Vera Therapeutics
    Via GlobeNewswire
    Tickers VERA
    Vera Therapeutics to Participate at September Investor Conferences
    From Vera Therapeutics
    Via GlobeNewswire
    Tickers VERA
    Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Vera Therapeutics
    Via GlobeNewswire
    Tickers VERA
    Vera Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results
    From Vera Therapeutics
    Via GlobeNewswire
    Tickers VERA
    Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Vera Therapeutics
    Via GlobeNewswire
    Tickers VERA
    Vera Therapeutics Announces Appointment of Industry Veteran David L. Johnson as Chief Operating Officer
    From Vera Therapeutics
    Via GlobeNewswire
    Tickers VERA
    Vera Therapeutics Appoints Christy J. Oliger to Board of Directors
    From Vera Therapeutics
    Via GlobeNewswire
    Tickers VERA
    Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Vera Therapeutics
    Via GlobeNewswire
    Tickers VERA
    Vera Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
    From Vera Therapeutics
    Via GlobeNewswire
    Tickers VERA
    Vera Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for Atacicept in Immunoglobulin A Nephropathy (IgAN)
    From Vera Therapeutics
    Via GlobeNewswire
    Tickers VERA
    Vera Therapeutics Presents 72-week eGFR Stabilization and Rapid Hematuria Improvement in Phase 2b ORIGIN Study of Atacicept in IgAN at the 61st European Renal Association Congress
    From Vera Therapeutics
    Via GlobeNewswire
    Tickers VERA
    Vera Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
    From Vera Therapeutics
    Via GlobeNewswire
    Tickers VERA
    Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Vera Therapeutics
    Via GlobeNewswire
    Tickers VERA
    Vera Therapeutics Announces Two Oral Presentations at the 61st European Renal Association Congress
    From Vera Therapeutics
    Via GlobeNewswire
    Tickers VERA
    Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
    From Vera Therapeutics
    Via GlobeNewswire
    Tickers VERA
    Vera Therapeutics to Participate at the 44th Annual TD Cowen Health Care Conference
    From Vera Therapeutics
    Via GlobeNewswire
    Tickers VERA
    Vera Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
    From Vera Therapeutics
    Via GlobeNewswire
    Tickers VERA
    Vera Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Class A Common Stock
    From Vera Therapeutics
    Via GlobeNewswire
    Tickers VERA
    Vera Therapeutics Announces Pricing of Upsized Public Offering of Class A Common Stock
    From Vera Therapeutics
    Via GlobeNewswire
    Tickers VERA
    Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock
    From Vera Therapeutics
    Via GlobeNewswire
    Tickers VERA
    Vera Therapeutics Presents Positive 72-Week Data Showing eGFR Stabilization in the Phase 2b ORIGIN Clinical Trial OLE in IgA Nephropathy
    From Vera Therapeutics
    Via GlobeNewswire
    Tickers VERA
    Vera Therapeutics Announces Appointment of Industry Veterans Robert Brenner, M.D. as Chief Medical Officer and William D. Turner as Chief Development Officer
    From Vera Therapeutics
    Via GlobeNewswire
    Tickers VERA
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.